The objective of this study was to determine cardiovascular event rates in diabetic patients and nondiabetic subjects from the REACH Registry with established coronary artery disease, cerebrovascular disease, peripheral arterial disease, or multiple risk factors for atherothrombosis. REACH is an international, prospective, and contemporaneous cohort of patients with ≥3 atherothrombotic risk factors only or established atherothrombotic disease, of which 30,043 have diabetes. The main outcomes after 1-year follow-up were cardiovascular death, myocardial infarction, stroke, major adverse cardiovascular events (MACEs; cardiovascular death, myocardial infarction, or stroke), and MACEs/hospitalization. The MACE rate at 1 year was positively related to the number of atherothrombotic anatomic sites in diabetic patients and nondiabetic subjects, and the rate was higher in those with (3.8%) than without (3.0%, p <0.001) diabetes. Diabetic patients with risk factors only had a lower MACE rate than nondiabetic subjects or diabetic patients with established atherothrombotic disease (2.2% vs 4.0% or 6.0%, respectively, p <0.001 for the 2 comparisons). These differences persisted after adjusting for gender and age. In conclusion, diabetic patients in the REACH Registry have an increased risk of cardiovascular events compared to nondiabetic subjects related to the number of atherothrombotic sites. Although increasing risk, diabetes may not be truly equivalent to previous atherothrombotic events on new cardiovascular event rates.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Cardiology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.N Engl J Med. 1998; 339: 229-234
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation. 2002; 106: 3143-3421
- The editor's roundtable: diabetes mellitus and coronary heart disease.Am J Cardiol. 2006; 98: 842-856
- Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction.Diabetologia. 2005; 48: 856-861
- Sex differences in the effect of diabetes duration on coronary heart disease mortality.Arch Intern Med. 2005; 165: 430-435
- Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction.Circulation. 2004; 109: 855-860
- Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults.Circulation. 2006; 114: 2217-2225
- Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women.Diabetologia. 2006; 49: 56-65
- NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.Diabetes. 2003; 52: 1210-1214
- Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.Diabetes Care. 2006; 29: 1220-1226
- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary.Eur Heart J. 2007; 28: 88-136
- International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.JAMA. 2006; 295: 180-189
- One-year cardiovascular event rates in outpatients with atherothrombosis.JAMA. 2007; 297: 1197-1206
- Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Server, et al.Diabetes Care. 2005; 28: 2595-2596
- Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study.Diabetes Care. 2006; 29: 575-580
- Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.Circulation. 2008; 117: 1945-1954
- Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects.Diabetes Care. 2005; 28: 2901-2907
- Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.Arch Intern Med. 2004; 164: 1438-1443
- Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease.Eur Heart J. 2003; 24: 1406-1413
- Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies.BMJ. 2002; 324: 939-942
Accepted: October 13, 2009
Received in revised form: October 13, 2009
Received: July 8, 2009
The REACH Registry is sponsored by Sanofi-Aventis (Paris, France), Bristol-Myers Squibb (Paris, France), and the Waksman Foundation (Tokyo, Japan).
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.